Entrada Therapeutics reported a quarterly loss of $0.95 per share, beating the Zacks Consensus Estimate for a loss of $1.06 by $0.11 per share. The loss was wider than the $0.42 per share loss in the year-ago quarter, but the earnings result was better than expected. The article contains no revenue or guidance update, so the likely market impact is limited to the stock itself.
Entrada Therapeutics reported a quarterly loss of $0.95 per share, beating the Zacks Consensus Estimate for a loss of $1.06 by $0.11 per share. The loss was wider than the $0.42 per share loss in the year-ago quarter, but the earnings result was better than expected. The article contains no revenue or guidance update, so the likely market impact is limited to the stock itself.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.22
Ticker Sentiment
